Ikena Oncology, Inc.
NASDAQ: IKNA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mark Manfredi
- Employees
- 10
- Headquarters
- Boston, United States
- IPO year
- 2021
- Market cap
- $718.8M
- Website
- https://ikenaoncology.com
Loading IKNA…
Loading profile data…Frequently asked questions about IKNA
What does Ikena Oncology, Inc. (IKNA) do?
Ikena Oncology, Inc. is a biopharmaceutical company specializing in precision oncology. Its primary objective is to create therapeutic agents specifically formulated for patient populations identified through biomarkers, thereby addressing significant unmet medical needs. The company's leading drug candidate is IK-930, an orally administered sma...
Where does IKNA trade?
Ikena Oncology, Inc. (IKNA) trades on the NASDAQ Global Market.
What sector is IKNA in?
Ikena Oncology, Inc. (IKNA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Ikena Oncology, Inc.?
Mark Manfredi is the chief executive officer of Ikena Oncology, Inc. (IKNA).
Where is Ikena Oncology, Inc. headquartered?
Ikena Oncology, Inc. is headquartered in United States.
Does IKNA pay a dividend?
Ikena Oncology, Inc. (IKNA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did IKNA go public?
Ikena Oncology, Inc. (IKNA) completed its initial public offering in 2021.